IRCT20210720051946N2 IRCT 2022-05-19 Shahid Beheshti University of Medical Sciences The effect of Montelukast administration on rhabdomyolysis state The effect of routine rhabdomyolysis treatment with and without concomitant administration of Montelukast on the stop progression and recovery time of rhabdomyolysis 2022-05-22 anticipated 60 Complete https://irct.ir/trial/60609 interventional Randomization: Randomized, Blinding: Single blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Through the table of numbers: 60 patients who have enough criteria for participation in this plan are written from number one to 60 then even numbers enter the intervention group and odd numbers enter the control group, Blinding description: For this study, patients with rhabdomyolysis (CPK> 1000) was selected from poisoning ward at Loghman Hakim Hospital in Tehran and divided into control and target groups: 1-Control group will receive routine rhabdomyolysis treatment by hydration therapy and bicarbonate therapy 2- Target group will receive hydration therapy with oral Montelukast or gavage at a dose of 10 mg twice daily. In this study, patients or their companions who enter the study are given consent to prescribe a new drug, but the control and target groups remain unaware of the type of treatment received and are kept blind. 3 Rhabdomyolysis. Intervention 1: Control group:Includes odd numbers in the numbered list of patients undergoing routine rhabdomyolysis (24-hour maintenance fluid therapy plus one liter of Normal saline per 1000 units of Cpk increase above 1000) while maximal normal saline is added intake is 4 liters in 24 hours. In cases of Cpk> 5000 , patients will receive only an infusion of 200 cc of 5% dextrose serum with 30 milliequivalents of Sodium bicarbonate per hour.Nephrology consultation will be performed for all patients and according to the Nephrologist, the patients who are candidates for dialysis for any reason will be removed from the plan and another patient will be replaced. Intervention 2: Intervention group: Includes even numbers in the numbered list of patients receiving treatment in the control group, but in addition, Montelukast tablets are taken as 10 mg every 12 hours orally or by gavage until the Cpk is reduced to less than 1000. This group patients, like the control group, if for any reason, according to the Nephrologist, are candidates for dialysis, they will be excluded from the plan and another patient will be replaced. Yes - There is a plan to make this available What will be shared: Data are age, sex, and test results of the control and target groups, and only part of the data can be shared When: Access will start from the time the results are printed To whom: Everyone Conditions: Allowed for scientific and medical uses Where to obtain: Email:peyman1346erfan@sbmu.ac.ir How to obtain: Email:peyman1346erfan@sbmu.ac.ir The applicant states the reason for her request by sending her request to the above email, and then within about two weeks, the general information of the patients without mentioning their names and details and the results of this research will be sent to him. Comments: